Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95064 | 0.82 | HPGD (0.65) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL11390038 | 0.75 | HPGD (0.64) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL12632572 | 0.75 | HSP90AA1 (0.60) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL20988805 | 0.74 | ALDH1A1 (0.53) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL10107755 | 0.71 | HSP90AA1 (0.66) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL8299002 | 0.71 | HSP90AA1 (0.65) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| Pyridine SCHEMBL5332991 | 0.71 | HPGD (0.59) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL11042714 | 0.71 | HPGD (0.56) | HPGDHSP90AA1MEN1KMT2AALDH1A1 | |
| SCHEMBL109220 | 0.70 | HPGD (0.70) | HPGDMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8349898 | 0.70 | TRPM8 (0.62) | HPGDHSP90AA1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134056-A1 | K-RAS MUTATIONS AND ANTAGONISTS | KRAS, NRAS, HRAS | HPGD 2600/4885HSP90AA1 1548/4885MEN1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.